Reproductive and Perinatal Pharmacoepidemiology

Reproductive pharmacoepidemiologic research investigates medication use, safety, and effectiveness related to all areas of human reproduction, including hormonal contraception, drugs for infertility treatment, medications used during pregnancy and the neonatal period, and pharmacological treatments related to menopause.

In this area, the main focus of researchers at CPE is to generate high-quality evidence towards the safety of medication use in pregnancy for both the mother and the child. We do so by leveraging the strengths of the Swedish population and quality registers in Nordic and international collaborations, in both academic projects and in regulatory-mandated post-authorization safety studies (PASS). 

In particular, we are currently studying medication used by pregnant women for treatment of depression and other psychiatric disorders, type 2 diabetes, epilepsy, chronic inflammatory diseases, migraine, and infection. 

Academic collaborations

The Nordic / International Pregnancy Drug Safety Studies (NorPreSS / InPreSS) consortium is a collaboration between investigators at institutions in the five Nordic countries, USA, and Australia. Recently, we have also collaborated with researchers from Hong Kong, Taiwan, South Korea, New Zealand, UK, Israel, and Germany. 

Together, we develop harmonized study protocols to address research questions with clinical relevance. Our goal is to provide timely and robust information on medication safety during pregnancy for women and their healthcare providers, clinical guidelines, and regulatory agencies. 

NorPreSS/InPreSS publications can be found at this link 

The research area is led by:

Carolyn Cesta


Publications on PubMed

Content reviewer: